| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kazutaka Uchida, Yoshiki Arakawa, Kenji Ohyama, Manabu Sirakawa, Rie Tsuji, Masao Yokoyama, Kiyoharu Imataka, Manabu Sato, Yukio Shimiz. Growth hormone-secreting pituitary adenoma associated with primary moyamoya disease--case report. Neurologia medico-chirurgica. vol 43. issue 7. 2003-09-30. PMID:12924597. |
a 40-year-old female presented with growth hormone (gh)-secreting pituitary adenoma associated with primary moyamoya disease manifesting as amenorrhea, acromegaly, and transient ischemic attack. |
2003-09-30 |
2023-08-12 |
Not clear |
| Susan M Webb, Felipe Casanueva, John A H Was. Oncological complications of excess GH in acromegaly. Pituitary. vol 5. issue 1. 2003-09-23. PMID:12638722. |
oncological complications of excess gh in acromegaly. |
2003-09-23 |
2023-08-12 |
Not clear |
| Susan M Webb, Felipe Casanueva, John A H Was. Oncological complications of excess GH in acromegaly. Pituitary. vol 5. issue 1. 2003-09-23. PMID:12638722. |
overall and cancer mortality in acromegaly have been shown to correlate with the degree of gh control; if post therapy gh is controlled, both the overall and cancer mortality do not appear to differ from that of the normal population (sm orme et al., j clin endocrinol metab 1998;83:2730-2734; jd nabarro, clin endocrinol 1987;26:481-512). |
2003-09-23 |
2023-08-12 |
Not clear |
| Fausto Bogazzi, Federica Ultimieri, Francesco Raggi, Dania Russo, Paolo Viacava, Denise Cecchetti, Aurelio Costa, Sandra Brogioni, Chiara Cosci, Maurizio Gasperi, Luigi Bartalena, Enio Martin. Changes in the expression of the peroxisome proliferator-activated receptor gamma gene in the colonic polyps and colonic mucosa of acromegalic patients. The Journal of clinical endocrinology and metabolism. vol 88. issue 8. 2003-09-11. PMID:12915690. |
serum gh and igf-i levels were higher in patients with untreated acromegaly than in those with acromegaly in remission or controls (p = 0.003 and p = 0.002, respectively) the expression of ppargamma mrna (mean +/- se) was 1) mucosa outside polyps, 24,188 +/- 3,254 transcripts in the controls, 22,432 +/- 2,006 transcripts in acromegaly in remission, and 1,952 +/- 342 transcripts in untreated acromegaly (p < 0.0001 vs. controls and acromegaly in remission); and 2) polyps mucosa, 1,554 +/- 236 transcripts in the controls, 1,112 +/- 143 in acromegaly in remission, and 1,570 +/- 251 in untreated acromegaly (p = ns among polyps groups and mucosa outside polyps of untreated acromegaly; p < 0.0001 vs. mucosa outside polyps of controls and acromegaly in remission). |
2003-09-11 |
2023-08-12 |
Not clear |
| Shlomo Melmed, Mary Lee Vance, Ariel L Barkan, Bengt-Ake Bengtsson, David Kleinberg, Anne Klibanski, Peter J Traine. Current status and future opportunities for controlling acromegaly. Pituitary. vol 5. issue 3. 2003-07-17. PMID:12812311. |
growth-hormone (gh) secreting adenomas, including acromegaly, account for approximately one-sixth of all pituitary adenomas and are associated with mortality rates at least twice that of the general population. |
2003-07-17 |
2023-08-12 |
Not clear |
| Shlomo Melmed, Mary Lee Vance, Ariel L Barkan, Bengt-Ake Bengtsson, David Kleinberg, Anne Klibanski, Peter J Traine. Current status and future opportunities for controlling acromegaly. Pituitary. vol 5. issue 3. 2003-07-17. PMID:12812311. |
novel new therapies for acromegaly include the somatostatin analog, lanreotide, gamma knife radiosurgery, and pegvisomant, the first in its class of new gh receptor antagonists. |
2003-07-17 |
2023-08-12 |
Not clear |
| G Lombardi, A Colao, P Marzullo, B Biondi, E Palmieri, S Fazi. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. Journal of endocrinological investigation. vol 25. issue 11. 2003-07-01. PMID:12553557. |
improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced gh and igf-i decrease in acromegaly. |
2003-07-01 |
2023-08-12 |
Not clear |
| D Gaia, V Gasco, P Razzore, E Ciccarelli, F Camanni, E Ghigo, S Grottol. GH but not IGF-I hypersecretion in acromegaly is generally attenuated in elderly acromegalics. Journal of endocrinological investigation. vol 25. issue 10 Suppl. 2003-06-13. PMID:12508916. |
gh but not igf-i hypersecretion in acromegaly is generally attenuated in elderly acromegalics. |
2003-06-13 |
2023-08-12 |
Not clear |
| O Kurtkaya-Yapicier, B W Scheithauer, J A Carney, K Kovacs, E Horvath, C A Stratakis, S Vidal, A Vella, W F Young, J L D Atkinson, R V Lloyd, G Kontogeorgo. Pituitary adenoma in Carney complex: an immunohistochemical, ultrastructural, and immunoelectron microscopic study. Ultrastructural pathology. vol 26. issue 6. 2003-06-04. PMID:12537759. |
patients with the latter present with elevated growth hormone (gh) levels and acromegaly or gigantism. |
2003-06-04 |
2023-08-12 |
Not clear |
| Nienke R Biermasz, Niels C van den Oever, Marijke Frölich, Alberto M Pereira Arias, Jan W A Smit, Johannes A Romijn, Ferdinand Roelfsem. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clinical endocrinology. vol 58. issue 3. 2003-05-30. PMID:12608933. |
sandostatin lar in acromegaly: a 6-week injection interval suppresses gh secretion as effectively as a 4-week interval. |
2003-05-30 |
2023-08-12 |
Not clear |
| Nienke R Biermasz, Niels C van den Oever, Marijke Frölich, Alberto M Pereira Arias, Jan W A Smit, Johannes A Romijn, Ferdinand Roelfsem. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clinical endocrinology. vol 58. issue 3. 2003-05-30. PMID:12608933. |
depot preparations of long-acting somatostatin analogues are being used increasingly in the treatment of gh hypersecretion in patients with acromegaly, either as primary treatment or as secondary treatment following incomplete surgery. |
2003-05-30 |
2023-08-12 |
Not clear |
| Pamela U Freda, Carlos M Reyes, Irene M Conwell, Robert E Sundeen, Sharon L Wardla. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy. The Journal of clinical endocrinology and metabolism. vol 88. issue 5. 2003-05-28. PMID:12727951. |
although exogenously administered ghrelin stimulates pituitary gh secretion, little is known about the role of ghrelin in endogenous gh secretion or how high gh and igf-i levels in acromegaly could affect ghrelin secretion and vice versa. |
2003-05-28 |
2023-08-12 |
human |
| Pamela U Freda, Carlos M Reyes, Irene M Conwell, Robert E Sundeen, Sharon L Wardla. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy. The Journal of clinical endocrinology and metabolism. vol 88. issue 5. 2003-05-28. PMID:12727951. |
ghrelin secretion is dysregulated in active acromegaly; lowered serum levels of ghrelin in active acromegaly rise along with the postsurgery normalization of gh and igf-i and improved insulin resistance. |
2003-05-28 |
2023-08-12 |
human |
| Ariel L Barkan, Eleni V Dimaraki, Stacy K Jessup, Kathleen V Symons, Mikhail Ermolenko, Craig A Jaff. Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels. The Journal of clinical endocrinology and metabolism. vol 88. issue 5. 2003-05-28. PMID:12727973. |
we studied plasma ghrelin and gh concentrations over a 24-h period in young healthy men and women and in patients with acromegaly. |
2003-05-28 |
2023-08-12 |
human |
| Ariel L Barkan, Eleni V Dimaraki, Stacy K Jessup, Kathleen V Symons, Mikhail Ermolenko, Craig A Jaff. Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels. The Journal of clinical endocrinology and metabolism. vol 88. issue 5. 2003-05-28. PMID:12727973. |
in the presence of high gh levels (acromegaly), ghrelin levels were similar to those found in healthy men. |
2003-05-28 |
2023-08-12 |
human |
| Georg Braban. Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. European journal of endocrinology. vol 148 Suppl 2. 2003-05-23. PMID:12670296. |
acromegaly is caused by chronic excess secretion of growth hormone (gh) and resultant persistent elevation in concentrations of insulin-like growth factor-i (igf-i), also called somatomedin-c. a number of diagnostic tests are available to support the diagnosis of acromegaly, but those that rely on measurement of serum gh concentrations have important limitations. |
2003-05-23 |
2023-08-12 |
Not clear |
| Georg Braban. Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. European journal of endocrinology. vol 148 Suppl 2. 2003-05-23. PMID:12670296. |
thus, serum igf-i is an important marker of disease activity and a sensitive, practical, and reliable measure of integrated gh concentrations in patients with acromegaly. |
2003-05-23 |
2023-08-12 |
Not clear |
| Paul M Stewar. Pegvisomant: an advance in clinical efficacy in acromegaly. European journal of endocrinology. vol 148 Suppl 2. 2003-05-23. PMID:12670298. |
acromegaly is a chronic disorder invariably caused by a growth hormone (gh)-secreting pituitary tumour and is characterised by disabling symptoms (sweating, arthralgia, headache, paraesthesiae, fatigue), significant comorbidities (diabetes mellitus, hypertension, sleep apnoea), and premature mortality. |
2003-05-23 |
2023-08-12 |
Not clear |
| Mary Lee Vanc. Medical treatment of functional pituitary tumors. Neurosurgery clinics of North America. vol 14. issue 1. 2003-05-02. PMID:12690980. |
a somatostatin analogue is effective medical therapy for patients with acromegaly, and this is usually administered if there is persistent gh hypersecretion after surgical resection. |
2003-05-02 |
2023-08-12 |
Not clear |
| R Wasko, J Sawicka, C Stachowiak, W Kozak, R Junik, J Sowinsk. [Effect of lanreotide on prolactin level in patients with pituitary mixed tumors]. Annales d'endocrinologie. vol 63. issue 6 Pt 1. 2003-03-25. PMID:12527855. |
acromegaly is a disease caused by a pituitary tumor (somatotropinoma) or by ectopic secretion of gh or igf-1. |
2003-03-25 |
2023-08-12 |
Not clear |